ASSESSMENT OF PROTEINURIA REPORTED AS ADVERSE EVENTS IN DE NOVO RENAL TRANSPLANT RECIPIENTS RECEIVING AN EVEROLIMUS-BASED REGIMEN: 24-MONTH RESULTS FROM TRANSFORM

被引：0
|
作者：
Legendre, C. [5 ]
Buchler, M. [7 ]
Pernin, V. [4 ]
Berger, S. P. [13 ]
Oppenheimer, F. [11 ]
Wiseman, A. [14 ]
Viklicky, O. [3 ]
Russ, G. R. [1 ]
Danguilan, R. [10 ]
Basic-Jukic, N. [2 ]
Mor, E. [9 ]
Narvekar, P. [12 ]
Hernandez-Gutierrez, M. P. [12 ]
Bernhardt, P. [12 ]
Gharbi, H. [6 ]
Sommerer, C. [8 ]
机构：
[1] Royal Adelaide Hosp, Cent & Northern Adelaide Renal & Transplantat Ser, Adelaide, SA, Australia
[2] Univ Hop Ctr Zagreb, Zagreb, Croatia
[3] Inst Clin & Expt Med, Dept Nephrol, Transplant Ctr, Prague, Czech Republic
[4] CHU Montpellier, Montpellier, France
[5] Hop Necker Enfants Malad, Paris, France
[6] Novartis Pharma SAS, Rueil Malmaison, France
[7] CHU Tours, Tours, France
[8] Univ Hosp Heidelberg, Dept Nephrol, Heidelberg, Germany
[9] Sheba Med Ctr, Ramat Gan, Israel
[10] Natl Kidney & Transplant Inst, Quezon City, Philippines
[11] Hosp Clin Barcelona, Dept Nephrol & Renal Transplantat, Barcelona, Spain
[12] Novartis Pharma AG, Basel, Switzerland
[13] Univ Med Ctr Groningen, Dept Nephrol, Groningen, Netherlands
[14] Univ Colorado, Sch Med, Aurora, CO USA
来源：
TRANSPLANT INTERNATIONAL | 2020年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
O2
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [1] Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM.
    Legendre, C.
    Berger, S.
    Oppenheimer, F.
    Wiseman, A.
    Steinberg, S.
    Viklicky, O.
    Russ, G.
    Danguilan, R.
    Basic-Jukic, N.
    Mor, E.
    Narvekar, P.
    Gutierrez, M. P. Hernandez
    Bernhardt, P.
    Sommerer, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 693 - 694
  • [2] EFFICACY AND SAFETY OF EVEROLIMUS-BASED REGIMEN IN RENAL TRANSPLANT RECIPIENTS WITH DELAYED GRAFT FUNCTION: 24-MONTH RESULTS FROM THE TRANSFORM STUDY
    Citterio, Franco
    Sommerer, Claudia
    Oppenheimer, Federico
    Berger, Stefan
    Viklicky, Ondrej
    Danguilan, Romina
    Basic-Jukic, Nikolina
    Hernandez, Maria-Pilar
    Narvekar, Prachiti
    Bernhardt, Peter
    Legendre, Christophe
    TRANSPLANT INTERNATIONAL, 2019, 32 : 80 - 80
  • [3] EFFECT OF TACROLIMUS EXPOSURE ON EVEROLIMUS-BASED IMMUNOSUPPRESSION IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: A 24-MONTH ANALYSIS FROM TRANSFORM STUDY
    Citterio, Franco
    Peddi, V. Ram
    Qazi, Yasir
    Kim, Dean
    Vincenti, Flavio
    Berger, Stefan
    Sommerer, Claudia
    Gawai, Apurva
    Hernandez-Gutierrez, Maria-Pilar
    Bernhardt, Peter
    Oberbauer, Rainer
    TRANSPLANT INTERNATIONAL, 2021, 34 : 254 - 255
  • [4] Antirejection Efficacy in De Novo Renal Transplant Recipients Receiving Everolimus with a Reduced-Exposure Calcineurin Inhibitor-Based Regimen: 24-Month Results from the TRANSFORM Study.
    Silva, H. Tedesco
    Citterio, F.
    Henry, M.
    Srinivas, T. R.
    Watarai, Y.
    Steinberg, S.
    Basic-Jukic, N.
    Garcia, V. D.
    Mor, E.
    Peddi, V. R.
    Narvekar, P.
    Gutierrez, M. P. Hernandez
    Bernhardt, P.
    Pascual, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 358 - 359
  • [5] EVEROLIMUS-BASED IMMUNOSUPPRESSION IN HCV POSITIVE DE NOVO LIVER TRANSPLANT RECIPIENTS: 24-MONTH RESULTS OF A RANDOMIZED CONTROLLED TRIAL
    Saliba, F.
    Metselaar, H. J.
    Beckebaum, S.
    Duvoux, C.
    Navasa, M.
    Dong, G.
    Lopez, P.
    Nevens, F.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S79 - S80
  • [6] De Novo Everolimus-Based Therapy in Renal Transplant Recipients: Effect on Proteinuria and Renal Prognosis
    Loriga, G.
    Ciccarese, M.
    Pala, P. G.
    Satta, R. P.
    Fanelli, V.
    Manca, M. L.
    Serra, G.
    Dessole, P.
    Cossu, M.
    TRANSPLANTATION PROCEEDINGS, 2010, 42 (04) : 1297 - 1302
  • [7] EFFECT OF DONOR AGE ON EFFICACY AND SAFETY OF DE NOVO RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-EXPOSURE CALCINEURIN INHIBITOR REGIMEN: 24-MONTH RESULTS FROM THE TRANSFORM STUDY
    Pascual, Julio
    Legendre, Christophe
    Vincenti, Flavio
    Tedesco, Helio
    Witzke, Oliver
    Viklicky, Ondrej
    Cruzado, Josep M.
    Hernandez, Maria-Pilar
    Narvekar, Prachiti
    Bernhardt, Peter
    Kuypers, Dirk
    TRANSPLANT INTERNATIONAL, 2019, 32 : 79 - 79
  • [8] EFFECT OF INDUCTION THERAPY ON OUTCOMES OF DE NOVO RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-DOSE CALCINEURIN INHIBITOR: 24-MONTH RESULTS FROM TRANSFORM STUDY
    Pernin, V.
    Legendre, C.
    Buchler, M.
    Oberbauer, R.
    Vincenti, F.
    Viklicky, O.
    Huynh-Do, U.
    Kim, D.
    Narvekar, P.
    Hernandez-Gutierrez, M. P.
    Bernhardt, P.
    Gharbi, H.
    Kuypers, D.
    TRANSPLANT INTERNATIONAL, 2020, 33 : 12 - 12
  • [9] Efficacy and Safety Outcomes by Donor Type in De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from Transform
    Berger, S.
    Bakr, M.
    Bemelman, F.
    Danguilan, R.
    De Fijter, H.
    Han, D.
    Kim, M.
    Mor, E.
    Patel, A.
    Gutierrez, M. Hernandez
    Gawai, A.
    Watarai, Y.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 942 - 943
  • [10] LIPID ABNORMALITIES AND CARDIOVASCULAR EVENTS IN RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-EXPOSURE CALCINEURIN INHIBITOR REGIMEN: 24-MONTH ANALYSIS FROM TRANSFORM STUDY
    Sommerer, Claudia
    Legendre, Christophe
    Citterio, Franco
    Watarai, Yoshihiko
    Oberbauer, Rainer
    Basic-Jukic, Nikolina
    Garcia, Valter Duro
    Peddi, V. Ram
    Hernandez-Gutierrez, Maria-Pilar
    Narvekar, Prachiti
    Bernhardt, Peter
    Chadban, Steve
    TRANSPLANT INTERNATIONAL, 2019, 32 : 71 - 71
12345